New research findings show how it may be possible to render cancer tumours harmless without affecting the other cells and tissues in the body. The findings apply to cancers including breast, lung and bowel cancer. The study was carried out at Lund University in Sweden. Many of the most common chemotherapy drugs used to treat cancer have serious side effects because they not only affect the cells in the cancer tumour, but also the cells in the rest of the body. Researchers at Lund University have now found a connection between two proteins that in different ways control cell division and the possibilities for a cancer tumour to develop. The retinoblastoma protein obstructs cell division and is absent in most types of cancer tumour. The new findings show that its absence leads to an increase in another protein, gamma-tubulin, which, when present in high levels, encourages the development of cancer tumours.
Although breast cancer-related fatigue is common, it generally runs a self-limiting course and does not persist as long as people had thought; especially in cases of early-stage breast cancer, researchers reported in the Journal of Clinical Oncology. The authors explained that long-term fatigue, which is often disabling, is common after patients undergo treatment for cancer. However, they added that studies had not extensively looked at how persistent CRF (cancer-related fatigue) was; i.e. how common long-term CRF might be. In an Abstract in the journal, the researchers wrote: ".. . hence, relationships to cancer, surgery, and adjuvant therapy are unclear. " Dr. David Goldstein, of Prince of Wales Hospital in Randwick, Australia, and team set out to determine how common cancer-related fatigue was one year after treatment.
" Cancer worry" is the fear that cancer will return, said researchers at Moffitt Cancer Center who studied cancer worry among breast cancer survivors and published their findings in Psycho-Oncology. They found that even three years after successful treatment, two-thirds of the 202 breast cancer survivors who participated in their study said they had "a moderate level of worry." "Little is known about the factors associated with cancer worry, " said paper lead author Paul B. Jacobsen, Ph.D., associate center director for Moffitt's Center for Population Sciences. "In order to evaluate those factors, this study examined associations between breast cancer worry and demographic factors, such as age, and clinical factors, such as having had chemotherapy, fatigue, greater symptom burden and greater perceived risk perception of recurrence.
New findings in breast cancer research by an international team of scientists contradict the prevailing belief that only basal-like cells with stem cell qualities can form invasive tumors. Research led by Ole William Petersen at the University of Copenhagen (CU) and Mina Bissell of the Lawrence Berkeley National Laboratory (Berkeley Lab) and has shown that luminal-like cells with no detectable stem cell qualities can generate larger tumors than their basal-like counterparts. This may hold important implications for the diagnosis and the treatment of breast cancer as well as future personalized cancer medicine. "It is fashionable to think of breast cancer as a disease that can be treated if cancer stem cells are killed off, but we are reporting a sub-population of cancer cells that have no obvious stem cell properties and yet can be tumorigenic and highly aggressive, " Bissell says.
Medicine-toting nanochains slip into tumors and explode a chemotherapy drug into hard-to-reach cores of cancer, engineers and scientists at Case Western Reserve University report. In tests on rats and mice, the technology took out far more cancer cells, inhibited tumor growth better and extended life longer than traditional chemotherapy delivery. All the while, the targeted delivery system used far less of the drug doxorubicin than the amount used in traditional chemotherapy, saving healthy tissue from toxic exposure. The new delivery system and results are described in the online edition of The American Chemical Society journal ACS Nano. "Other nanotechnology has been used to get a drug inside a tumor, but once the drug gets in the door, it stays by the door, missing most of the building, " said Efstathios Karathanasis, a biomedical engineering professor and leader of the research team.